Rib-X Pharmaceuticals Appoints John E. Sununu to the Board of Directors

Rib-X Pharmaceuticals Appoints John E. Sununu to the Board of Directors

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rib-X Pharmaceuticals, Inc. today announced the appointment of former U.S. Senator John E. Sununu to the Board of Directors.

"Addressing the public health crisis posed by drug resistant superbugs will require the dedicated efforts of multiple stakeholders across the healthcare industry, government, advocacy and financial communities"
"Senator Sununu brings a wealth of talent and expertise to the Rib-X team," commented Mary T. Szela, Rib-X's Chief Executive Officer. "His unique combination of policy, financial, and technical experience will be enormously valuable to Rib-X at a pivotal time for the Company. I am excited to welcome John to the Rib-X team and look forward to his contributions as we advance our pipeline of novel antibiotic candidates, including the initiation of multiple pivotal studies with our broad spectrum antibiotic, delafloxacin."

"Addressing the public health crisis posed by drug resistant superbugs will require the dedicated efforts of multiple stakeholders across the healthcare industry, government, advocacy and financial communities," said Senator Sununu. "I am very excited to join the talented and dedicated team at Rib-X as a Board Director and look forward to working with the Company as they strive to deliver much needed new antibiotics to patients in need."

From 2003 to 2009, Senator Sununu served as a U.S. Senator from New Hampshire. During his time in the Senate, he was a member of the Committees on Banking, Commerce, Finance and Foreign Relations, and he was appointed the Congressional Representative to the United Nations General Assembly. Prior to his election to the Senate, Senator Sununu served three terms as a Member of the U.S. House of Representatives from New Hampshire's 1st District from 1996 to 2002. He was Vice Chairman of the Budget Committee and a member of the Appropriations Committee. During his 12 years in Congress, he drafted and helped pass several important pieces of legislation, including the Internet Tax Freedom Act, the Survivors Benefit Act and the New England Wilderness Act.

Before entering public service, Senator Sununu worked for emerging high-tech firms and served as Chief Financial Officer of Teletrol Systems, a manufacturer of building control systems, from 1993 to 1996. Currently, he serves on the board of directors of Time Warner Cable, Inc. and Boston Scientific. He holds B.S. and M.S. degrees in Mechanical Engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.

About Rib-X

Rib-X Pharmaceuticals, Inc. is a biopharmaceutical company developing new antibiotics to provide superior coverage, safety and convenience for the treatment of serious and life-threatening infections. The Company's proprietary drug discovery platform is based on Nobel Prize-winning science and provides an atomic-level, three-dimensional understanding of interactions between drug candidates and their bacterial targets to enable the design of antibiotics with enhanced characteristics. Rib-X's lead program is delafloxacin, an enhanced spectrum IV/oral antibiotic intended for use as first-line monotherapy to treat multiple bacterial diseases, which completed a Phase 2b clinical trial for the treatment of acute bacterial skin and skin structure infections. The Company's pipeline also includes its late-preclinical RX-04 program targeting multidrug-resistant and extremely-drug-resistant Gram-negative infections and other discovery stage anti-infective programs. Rib-X is privately held and backed by Vatera Healthcare Partners and Warburg Pincus, among others. For more information, please visit www.rib-x.com.

Contacts

Company:
Bob Conerly, 203-624-5606
[email protected]
or
Media Relations:
Kari Watson, 781-235-3060
[email protected]

Email

 

Suggested Articles

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.

The phase 2/3 clinical trial linked REGN-COV2 to a 57% decline in medical visits associated with COVID-19 in the 29 days after treatment.

Drug companies often face steep challenges when entering new markets for the first time. LianBio is here to help.